1061 — Essex Bio-Technology Balance Sheet
0.000.00%
- HK$2.49bn
- HK$2.12bn
- HK$1.67bn
- 89
- 72
- 96
- 98
Annual balance sheet for Essex Bio-Technology, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 600 | 671 | 543 | 515 | 561 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 516 | 714 | 500 | 637 | 617 |
Total Inventory | |||||
Total Other Current Assets | |||||
Total Current Assets | 1,333 | 1,547 | 1,214 | 1,245 | 1,283 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 280 | 352 | 401 | 406 | 414 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 2,421 | 2,863 | 2,712 | 2,828 | 2,983 |
Accounts Payable | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 606 | 690 | 561 | 811 | 709 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Total Liabilities | 995 | 1,129 | 981 | 904 | 859 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Unrealized Gain / Loss | |||||
Other Equity | |||||
Total Equity | 1,426 | 1,734 | 1,731 | 1,924 | 2,124 |
Total Liabilities & Shareholders' Equity | 2,421 | 2,863 | 2,712 | 2,828 | 2,983 |
Total Common Shares Outstanding |